These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

223 related articles for article (PubMed ID: 32591776)

  • 1. TBR-760, a Dopamine-Somatostatin Compound, Arrests Growth of Aggressive Nonfunctioning Pituitary Adenomas in Mice.
    Halem HA; Hochgeschwender U; Rih JK; Nelson R; Johnson GA; Thiagalingam A; Culler MD
    Endocrinology; 2020 Aug; 161(8):. PubMed ID: 32591776
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy of a dopamine-somatostatin chimeric molecule, BIM-23A760, in the control of cell growth from primary cultures of human non-functioning pituitary adenomas: a multi-center study.
    Florio T; Barbieri F; Spaziante R; Zona G; Hofland LJ; van Koetsveld PM; Feelders RA; Stalla GK; Theodoropoulou M; Culler MD; Dong J; Taylor JE; Moreau JP; Saveanu A; Gunz G; Dufour H; Jaquet P
    Endocr Relat Cancer; 2008 Jun; 15(2):583-96. PubMed ID: 18509006
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Characterization of the ability of a, second-generation SST-DA chimeric molecule, TBR-065, to suppress GH secretion from human GH-secreting adenoma cells.
    Cuny T; Graillon T; Defilles C; Datta R; Zhang S; Figarella-Branger D; Dufour H; Mougel G; Brue T; Landsman T; Halem HA; Culler MD; Barlier A; Saveanu A
    Pituitary; 2021 Jun; 24(3):351-358. PubMed ID: 33433890
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Balance between somatostatin and D2 receptor expression drives TSH-secreting adenoma response to somatostatin analogues and dopastatins.
    Gatto F; Barbieri F; Gatti M; Wurth R; Schulz S; Ravetti JL; Zona G; Culler MD; Saveanu A; Giusti M; Minuto F; Hofland LJ; Ferone D; Florio T
    Clin Endocrinol (Oxf); 2012 Mar; 76(3):407-14. PubMed ID: 21848909
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Somatostatin and dopamine-somatostatin multiple ligands directed towards somatostatin and dopamine receptors in pituitary adenomas.
    Saveanu A; Gunz G; Guillen S; Dufour H; Culler MD; Jaquet P
    Neuroendocrinology; 2006; 83(3-4):258-63. PubMed ID: 17047391
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Somatostatin analogs and chimeric somatostatin-dopamine molecules differentially regulate human growth hormone and prolactin gene expression and secretion in vitro.
    Gruszka A; Culler MD; Melmed S
    Mol Cell Endocrinol; 2012 Oct; 362(1-2):104-9. PubMed ID: 22705877
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A New Generation Somatostatin-Dopamine Analogue Exerts Potent Antitumoral Actions on Pituitary Neuroendocrine Tumor Cells.
    Vázquez-Borrego MC; L-López F; Gálvez-Moreno MA; Fuentes-Fayos AC; Venegas-Moreno E; Herrera-Martínez AD; Blanco-Acevedo C; Solivera J; Landsman T; Gahete MD; Soto-Moreno A; Culler MD; Castaño JP; Luque RM
    Neuroendocrinology; 2020; 110(1-2):70-82. PubMed ID: 31272096
    [TBL] [Abstract][Full Text] [Related]  

  • 8. BIM-23A760, a chimeric molecule directed towards somatostatin and dopamine receptors, vs universal somatostatin receptors ligands in GH-secreting pituitary adenomas partial responders to octreotide.
    Jaquet P; Gunz G; Saveanu A; Barlier A; Dufour H; Taylor J; Dong J; Kim S; Moreau JP; Culler MD
    J Endocrinol Invest; 2005; 28(11 Suppl International):21-7. PubMed ID: 16625841
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Somatostatinergic ligands in dopamine-sensitive and -resistant prolactinomas.
    Fusco A; Gunz G; Jaquet P; Dufour H; Germanetti AL; Culler MD; Barlier A; Saveanu A
    Eur J Endocrinol; 2008 May; 158(5):595-603. PubMed ID: 18426817
    [TBL] [Abstract][Full Text] [Related]  

  • 10. BIM-23A760 influences key functional endpoints in pituitary adenomas and normal pituitaries: molecular mechanisms underlying the differential response in adenomas.
    Ibáñez-Costa A; López-Sánchez LM; Gahete MD; Rivero-Cortés E; Vázquez-Borrego MC; Gálvez MA; de la Riva A; Venegas-Moreno E; Jiménez-Reina L; Moreno-Carazo A; Tinahones FJ; Maraver-Selfa S; Japón MA; García-Arnés JA; Soto-Moreno A; Webb SM; Kineman RD; Culler MD; Castaño JP; Luque RM
    Sci Rep; 2017 Feb; 7():42002. PubMed ID: 28181484
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [New medical treatments in pituitary adenomas].
    Drutel A; Caron P; Archambeaud F
    Ann Endocrinol (Paris); 2008 Sep; 69 Suppl 1():S16-28. PubMed ID: 18954854
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effect of selective sst1, sst2, sst5 somatostatin receptors agonists, a somatostatin/dopamine (SST/DA) chimera and bromocriptine on the "clinically non-functioning" pituitary adenomas in vitro.
    Gruszka A; Kunert-Radek J; Radek A; Pisarek H; Taylor J; Dong JZ; Culler MD; Pawlikowski M
    Life Sci; 2006 Jan; 78(7):689-93. PubMed ID: 16115652
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Demonstration of enhanced potency of a chimeric somatostatin-dopamine molecule, BIM-23A387, in suppressing growth hormone and prolactin secretion from human pituitary somatotroph adenoma cells.
    Saveanu A; Lavaque E; Gunz G; Barlier A; Kim S; Taylor JE; Culler MD; Enjalbert A; Jaquet P
    J Clin Endocrinol Metab; 2002 Dec; 87(12):5545-52. PubMed ID: 12466351
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of chimeric molecules directed towards multiple somatostatin and dopamine receptors on inhibition of GH and prolactin secretion from GH-secreting pituitary adenomas classified as partially responsive to somatostatin analog therapy.
    Jaquet P; Gunz G; Saveanu A; Dufour H; Taylor J; Dong J; Kim S; Moreau JP; Enjalbert A; Culler MD
    Eur J Endocrinol; 2005 Jul; 153(1):135-41. PubMed ID: 15994755
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Relevance of coexpression of somatostatin and dopamine D2 receptors in pituitary adenomas.
    Saveanu A; Jaquet P; Brue T; Barlier A
    Mol Cell Endocrinol; 2008 May; 286(1-2):206-13. PubMed ID: 18241980
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Somatostatin receptor-specific analogs: effects on cell proliferation and growth hormone secretion in human somatotroph tumors.
    Danila DC; Haidar JN; Zhang X; Katznelson L; Culler MD; Klibanski A
    J Clin Endocrinol Metab; 2001 Jul; 86(7):2976-81. PubMed ID: 11443154
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of novel somatostatin-dopamine chimeric drugs in 2D and 3D cell culture models of neuroendocrine tumors.
    Herrera-Martínez AD; van den Dungen R; Dogan-Oruc F; van Koetsveld PM; Culler MD; de Herder WW; Luque RM; Feelders RA; Hofland LJ
    Endocr Relat Cancer; 2019 Jun; 26(6):585-599. PubMed ID: 30939452
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Somatostatin-dopamine chimeras: a novel approach to treatment of neuroendocrine tumors.
    Culler MD
    Horm Metab Res; 2011 Nov; 43(12):854-7. PubMed ID: 21989554
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Somatostatin receptor subtypes mRNA in TSH-secreting pituitary adenomas: a case showing a dramatic reduction in tumor size during short octreotide treatment.
    Horiguchi K; Yamada M; Umezawa R; Satoh T; Hashimoto K; Tosaka M; Yamada S; Mori M
    Endocr J; 2007 Jun; 54(3):371-8. PubMed ID: 17420609
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Somatostatin receptor sst2 gene transfer in human prolactinomas in vitro: impact on sensitivity to dopamine, somatostatin and dopastatin, in the control of prolactin secretion.
    Cuny T; Mohamed A; Graillon T; Roche C; Defilles C; Germanetti AL; Couderc B; Figarella-Branger D; Enjalbert A; Barlier A; Saveanu A
    Mol Cell Endocrinol; 2012 May; 355(1):106-13. PubMed ID: 22348806
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.